Abstract #1219 Open-Label Phase 2 Study to Assess Safety and Efficacy Of Relacorilant (Cort125134), A Selective Cortisol Modulator, in the Treatment of Endogenous Hypercortisolism

Andreas Moraitis; Nidhi Agrawal; Irina Bancos; Francesco Celi; Murray Gordon; Atil Kargi; Sam Lerman; Cary Mariash; Julie Silverstein; Margaret Wierman

doi:10.1016/S1530-891X(20)47511-1

Back

Abstract #1219 Open-Label Phase 2 Study to Assess Safety and Efficacy Of Relacorilant (Cort125134), A Selective Cortisol Modulator, in the Treatment of Endogenous Hypercortisolism

Journal article

Peer reviewed

Abstract #1219 Open-Label Phase 2 Study to Assess Safety and Efficacy Of Relacorilant (Cort125134), A Selective Cortisol Modulator, in the Treatment of Endogenous Hypercortisolism

Andreas Moraitis, Nidhi Agrawal, Irina Bancos, Francesco Celi, Murray Gordon, Atil Kargi, Sam Lerman, Cary Mariash, Julie Silverstein and Margaret Wierman

Endocrine practice, Vol.24, pp.314-315

2018-04

DOI: https://doi.org/10.1016/S1530-891X(20)47511-1

Metrics

39 Record Views

Details

Title: Abstract #1219 Open-Label Phase 2 Study to Assess Safety and Efficacy Of Relacorilant (Cort125134), A Selective Cortisol Modulator, in the Treatment of Endogenous Hypercortisolism
Creators: Andreas Moraitis
Nidhi Agrawal
Irina Bancos
Francesco Celi
Murray Gordon
Atil Kargi
Sam Lerman
Cary Mariash
Julie Silverstein
Margaret Wierman
Publication Details: Endocrine practice, Vol.24, pp.314-315
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Endocrinology, Diabetes & Metabolism
Language: English
Resource Type: Journal article
Record Identifier: 991031714271002976